Even though obesity is a significant public health concern that poses a substantial socioeconomic burden on the U.S. healthcare system, the reimbursement environment for antiobesity agents is very challenging. With limited options, the unmet need for safe and effective therapies remains high. Phentermine, widely available as a low-cost generic and frequently used as a first-line therapy, is indicated only for three months. Other approved antiobesity agents, such as Novo Nordisk’s Saxenda (liraglutide), Vivus’s Qsymia (phentermine / topiramate), and Currax Pharmaceuticals’ Contrave (naltrexone / bupropion) have high out-of-pocket costs. This report offers insight into payer policies regarding prescription weight-loss agents and their impact on physician prescribing, as well as how payer policy may change in the near future as awareness of obesity as a disease grows.
Geography: United States
Primary research: Survey of 91 U.S. endocrinologists and survey of 31 U.S. managed care organization (MCO) pharmacy directors (PDs)
Key drugs covered: Saxenda, Qsymia, Contrave, Xenical
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.